Social Restrictions versus Testing Campaigns in the COVID-19 Crisis: A Predictive Model Based on the Spanish Case.
COVID-19
/ economics
Communicable Disease Control
/ methods
Cost-Benefit Analysis
Government
Gross Domestic Product
Health Care Costs
Health Policy
/ economics
Humans
Mass Screening
Models, Economic
Models, Theoretical
Molecular Diagnostic Techniques
Pandemics
/ economics
SARS-CoV-2
Spain
/ epidemiology
COVID-19
SEIR
economic impact
health policy
molecular test
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
15 05 2021
15 05 2021
Historique:
received:
23
03
2021
revised:
10
05
2021
accepted:
12
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
16
6
2021
Statut:
epublish
Résumé
The global COVID-19 spread has forced countries to implement non-pharmacological interventions (NPI) (i.e., mobility restrictions and testing campaigns) to preserve health systems. Spain is one of the most severely impacted countries, both clinically and economically. In an effort to support policy decision-making, we aimed to assess the impacts of different NPI on COVID-19 epidemiology, healthcare costs and Gross Domestic Product (GDP). A modified Susceptible-Exposed-Infectious-Removed epidemiological model was created to simulate the pandemic evolution. Its output was used to populate an economic model to quantify healthcare costs and GDP variation through a regression model which correlates NPI and GDP change from 42 countries. Thirteen scenarios combining different NPI were consecutively simulated in the epidemiological and economic models. Both increased testing and stringency could reduce cases, hospitalizations and deaths. While policies based on increased testing rates lead to higher healthcare costs, increased stringency is correlated with greater GDP declines, with differences of up to 4.4% points. Increased test sensitivity may lead to a reduction of cases, hospitalizations and deaths and to the implementation of pooling techniques that can increase throughput testing capacity. Alternative strategies to control COVID-19 spread entail differing economic outcomes. Decision-makers may utilize this tool to identify the most suitable strategy considering epidemiological and economic outcomes.
Identifiants
pubmed: 34063465
pii: v13050917
doi: 10.3390/v13050917
pmc: PMC8157049
pii:
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Lancet Public Health. 2020 Nov;5(11):e568
pubmed: 33075295
Rev Clin Esp. 2020 Nov;220(8):480-494
pubmed: 33994573
Immunity. 2020 Nov 17;53(5):925-933.e4
pubmed: 33129373
Nat Hum Behav. 2021 Apr;5(4):529-538
pubmed: 33686204
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Clin Infect Dis. 2021 Nov 2;73(9):e3042-e3046
pubmed: 33532847
Nature. 2021 Jan 14;:
pubmed: 33441993
Radiology. 2020 Sep;296(3):E145-E155
pubmed: 32301646
Nat Med. 2020 Aug;26(8):1205-1211
pubmed: 32546824
BMC Med. 2020 Oct 9;18(1):321
pubmed: 33032601
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Lancet Public Health. 2020 Nov;5(11):e576
pubmed: 33045185
N Engl J Med. 2020 Oct 29;383(18):e101
pubmed: 32897661
Science. 2020 Nov 20;370(6519):895-897
pubmed: 33214256
PLoS Comput Biol. 2017 Sep 12;13(9):e1005697
pubmed: 28898249
Transfusion. 2015 Sep;55(9):2246-55
pubmed: 26103564
Nat Biotechnol. 2020 Sep;38(9):1021-1024
pubmed: 32820257
Lancet. 2020 Nov 7;396(10261):1525-1534
pubmed: 32979936
Am J Infect Control. 2021 Jan;49(1):21-29
pubmed: 32659413
PLoS One. 2020 Oct 21;15(10):e0240775
pubmed: 33085693
Lancet. 2018 Jun 2;391(10136):2236-2271
pubmed: 29893224
Farm Hosp. 2020 Jun 12;44(7):11-16
pubmed: 32533662
Sci Data. 2020 Oct 8;7(1):345
pubmed: 33033256